ArticleTherapeutic advances in ophthalmology
Multi-omics analysis unveils the role of lipid metabolism-derived acylation modifications in POAG and its potential implications.
Article in Therapeutic advances in ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Primary open-angle glaucoma (POAG) is a leading cause of vision loss, with lipid metabolism implicated in its pathogenesis. Our study explores lipid metabolism-derived acylation modifications in POAG using GEO, GWAS, and PubChem databases. Methods: Integrated multi-omics approaches were employed: Mendelian randomization assessed causal relationships between lipid traits and POAG risk; transcriptomic analysis (gene set variation analysis, weighted gene co-expression network analysis) identified key acylation-related genes; machine learning selected feature genes; and single-cell sequencing validated mechanisms in human trabecular meshwork samples. Results: Four lipid metabolism-derived acylations (palmitoylation, myristoylation, succinylation, malonylation) were significantly upregulated in POAG. Core genes 5'-aminolevulinate synthase 2 (ALAS2) and phospholipase C epsilon 1 (PLCE1) were mechanistically linked: ALAS2 catalyzed acyl-CoA accumulation, while myristoylated PLCE1 promoted trabecular fibrosis via collagen type IV alpha 3 chain interaction. External datasets confirmed these findings. Conclusion: Lipid-derived acylations drive POAG through ALAS2-mediated acyl-CoA production and PLCE1-induced fibrosis, revealing novel targets for intervention. Lipid metabolism-derived acylation modifications, particularly succinylation, propionylation, and myristoylation, may play a crucial role in POAG. These findings highlight the potential role of acylation modifications in POAG and offer new insights into POAG's molecular mechanisms and potential research directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.